# 2025年12月26日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. Runx2 在调控造血干细胞扩增中居于核心地位

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41447456)
**期刊：** Blood
**PMID：** 41447456
**DOI：** 10.1182/blood.2025031276

### 第一部分 原文与翻译

**英文原标题：** Runx2 takes center stage in regulating HSC expansion.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

该文献标题表明 Runx2 作为关键转录因子，在造血干细胞（HSC）扩增调控中起重要作用。尽管目前尚无正式摘要，但推测研究可能探讨 Runx2 对干细胞自我更新与分化平衡的调控机制，或其在造血系统重建与再生医学中的潜在应用。该研究有望揭示影响造血干细胞命运的新分子通路，为干细胞扩增策略提供理论支持。

---

## 2. Acalabrutinib 攻克体弱患者中的慢性淋巴细胞白血病

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41447452)
**期刊：** Blood
**PMID：** 41447452
**DOI：** 10.1182/blood.2025030747

### 第一部分 原文与翻译

**英文原标题：** Acalabrutinib to assail CLL in the frail.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文标题提示本研究聚焦于在体弱或伴有合并症患者中应用BTK抑制剂Acalabrutinib治疗慢性淋巴细胞白血病（CLL）的临床潜力。尽管未提供摘要，但推测作者可能探讨了该药在老年或不耐受人群中的疗效与安全性。研究主题具有现实意义，因为此类患者往往在接受高强度化疗时耐受性较差。对Acalabrutinib此类第二代BTK抑制剂的评估，有望进一步优化CLL治疗策略，同时也需关注长期安全性和耐药机制。

---

## 3. 房颤脉冲场消融术后出现的致命性延迟性心肌缺血和恶性心律失常。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41446933)
**期刊：** Circulation
**PMID：** 41446933
**DOI：** 10.1161/CIRCULATIONAHA.125.077983

### 第一部分 原文与翻译

**英文原标题：** Life-Threatening Delayed Myocardial Ischemia and Malignant Arrhythmias Occurring After Pulsed Field Ablation of Atrial Fibrillation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究报道了房颤脉冲场消融术后的严重并发症，包括延迟发作的心肌缺血和恶性心律失常。尽管脉冲场消融被认为具有高度选择性和较好的安全性，但该病例提示仍需警惕潜在的致命风险。研究的临床意义在于提醒医生在术后长期随访中关注延迟并发症的可能性。然而，由于缺乏详细摘要和系统性数据，其结论仍需更多案例与机制研究加以验证。

---

## 4. 抑制RACGAP1通过调控CPT1A依赖的脂肪酸代谢使三阴性乳腺癌细胞对铁死亡敏感。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444950)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41444950
**DOI：** 10.1186/s13046-025-03568-4

### 第一部分 原文与翻译

**英文原标题：** Inhibition of RACGAP1 sensitizes triple-negative breast cancer cells to ferroptosis by regulating CPT1A-dependent fatty acid metabolism.

> **英文摘要：**
> BACKGROUND: Triple-negative breast cancer (TNBC) is highly aggressive tumor with limited therapeutic options. Studying the molecular mechanisms underlying TNBC is necessary to address the unmet need in novel therapeutic targets. TNBC is demonstrated to have robust fatty acid (FA) metabolism activity, and recent studies proposed the linkage of FA metabolism with ferroptosis sensitivity. Hence, this study aimed to explore the targets that may regulate FA metabolism to sensitize TNBC cells to ferroptosis.
> 
> METHODS: RNA-sequencing data in The Cancer Genome Atlas (TCGA) and four microarray datasets in Gene Expression Omnibus (GEO) database were analyzed to identify key target RACGAP1, followed by a series of functional experiments to explore the exact role of RACGAP1 in two TNBC cell lines (human MDA-MB-231 and mouse 4T1) and Xenograft tumor model. Dual-luciferase and chromatin immunoprecipitation (ChIP) assay was utilized to verify the binding of RACGAP1 and MAZ. RNA sequencing on 4T1 cells transfecting with sh-NC and sh-RACGAP1 was performed to validate the actions of RACGAP1.
> 
> RESULTS: RACGAP1 was highly expressed in breast cancer, and associated with poor prognosis and ferroptosis activity. RACGAP1 silencing could inhibit tumor cells survival and promote ferroptosis, and such anti-tumor activity could be blocked by ferroptosis inhibitors. RNA-sequencing analysis suggested that RACGAP1 silencing could inhibit FA metabolism activity, which was further confirmed by metabolic analysis and the reduced level of ATP, triglyceride and FA oxidation. CPT1A overexpression reversed such changes, indicating that the regulation of RACGAP1 on FA metabolism was CPT1A-dependent. Activation of FA metabolism activity or CPT1A overexpression blocked the ferroptosis sensitivity induced by RACGAP1 silencing. Transcription factor MAZ was identified to directly up-regulate the expression of RACGAP1.
> 
> CONCLUSION: Inhibition of RACGAP1 sensitized TNBC cells to ferroptosis by inhibiting CPT1A-mediated FA metabolism. Targeting RACGAP1 might be feasible strategy for TNBC management.

> **中文摘要：**
> 背景：三阴性乳腺癌（TNBC）是一种侵袭性极强且治疗选择有限的肿瘤。研究TNBC的分子机制对于发现新的治疗靶点以满足尚未满足的临床需求具有重要意义。已有研究表明，TNBC具有显著的脂肪酸（FA）代谢活性，且近期研究提出FA代谢与铁死亡敏感性相关。因此，本研究旨在探索可能调控FA代谢、从而增强TNBC细胞对铁死亡敏感性的靶点。
> 
> 方法：分析癌症基因组图谱（TCGA）中的RNA测序数据及基因表达汇编（GEO）数据库中的四个微阵列数据集，以识别关键靶点RACGAP1。随后，在两种TNBC细胞系（人MDA-MB-231和小鼠4T1）及异种移植瘤模型中进行一系列功能实验，以探讨RACGAP1的具体作用。采用双荧光素酶报告实验和染色质免疫沉淀（ChIP）实验验证RACGAP1与MAZ的结合。对转染sh-NC和sh-RACGAP1的4T1细胞进行RNA测序，以验证RACGAP1的作用。
> 
> 结果：RACGAP1在乳腺癌中高表达，并与不良预后和铁死亡活性相关。沉默RACGAP1可抑制肿瘤细胞存活并促进铁死亡，而这种抗肿瘤作用可被铁死亡抑制剂阻断。RNA测序分析显示，沉默RACGAP1可抑制FA代谢活性，该结果通过代谢分析及ATP、甘油三酯和脂肪酸氧化水平下降得到进一步验证。CPT1A过表达可逆转这些变化，提示RACGAP1对FA代谢的调控依赖于CPT1A。激活FA代谢活性或CPT1A过表达可阻断由RACGAP1沉默引起的铁死亡敏感性。进一步鉴定发现转录因子MAZ可直接上调RACGAP1的表达。
> 
> 结论：抑制RACGAP1通过抑制CPT1A介导的FA代谢，使TNBC细胞对铁死亡敏感。靶向RACGAP1可能成为TNBC治疗的一种可行策略。

### 第二部分 AI 大师评价

本研究揭示RACGAP1作为调控CPT1A依赖性脂肪酸代谢的重要分子，可显著影响三阴性乳腺癌细胞的铁死亡敏感性。作者通过大规模数据筛选与体内外实验相结合，系统阐明了RACGAP1在调控代谢与细胞死亡途径间的关键作用。该研究的创新性在于发现了RACGAP1–CPT1A轴作为潜在的新型治疗靶点，为破解TNBC铁死亡耐受提供了思路。局限性在于尚需临床层面的验证及对其上游调控网络的更深入研究。

---

## 5. 组蛋白去乙酰化酶 HDAC7 限制 CD8 + T 细胞肿瘤浸润并降低膀胱癌免疫治疗敏感性：松柏素可逆转此效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444923)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41444923
**DOI：** 10.1186/s13046-025-03585-3

### 第一部分 原文与翻译

**英文原标题：** Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin.

> **英文摘要：**
> BACKGROUND: The limited response rate and substantial interindividual variability in immunotherapy outcomes remain major barriers to improving prognosis in patients with bladder cancer (BCa). As central effectors of antitumor immunity, the extent of CD8 + T cell infiltration into tumors is a key determinant of immunotherapy response. Members of the histone deacetylase (HDAC) family play critical roles in modulating tumor immune evasion and sensitivity to immunotherapy, making HDAC inhibitors of clinical interest.
> 
> METHODS: A retrospective analysis was performed using data from the IMvigor210 clinical trial and follow-up data from patients with locally advanced BCa who received adjuvant immunotherapy at our center, assessing the association between HDAC1-11 expression and immunotherapy response. RNA sequencing, gene set enrichment analysis (GSEA), chromatin immunoprecipitation PCR (ChIP-PCR), co-immunoprecipitation (Co-IP), mass spectrometry, lysine site mutagenesis, RNA immunoprecipitation, and bioinformatics analysis were employed to outline the HDAC7-BTRC-SRSF7-CCL5 pathway. The immunoregulatory function of HDAC7 was evaluated using CD8 + T cell co-culture assays and tumor models in humanized NOG (HuNOG) mice. Virtual screening, MicroScale Thermophoresis (MST), and HDAC activity assays were conducted to identify potential HDAC7 specific inhibitor. The immunosensitizing effect of Pinocembrin on BCa immunotherapy was validated using a C57BL/6 mouse tumor-bearing model.
> 
> RESULTS: Among the HDAC family members, only HDAC7 expression was significantly associated with immunotherapy response. HDAC7 was overexpressed in BCa and correlated with poorer prognosis. Functional assays demonstrated that HDAC7 suppresses CD8 + T cell infiltration, thereby reducing sensitivity to PD-1 antibody treatment. Mechanistically, HDAC7 reduced acetylation at lysine 24 of the splicing regulator SRSF7, enhancing BTRC-mediated ubiquitination and degradation of SRSF7, which promoted the processing and expression of CCL5 mRNA-a chemokine essential for CD8 + T cell recruitment. Furthermore, Pinocembrin was identified as a selective HDAC7 inhibitor that restores CD8 + T cell infiltration and improves immunotherapy efficacy in BCa.
> 
> CONCLUSIONS: HDAC7 represents a promising diagnostic and therapeutic target in BCa immunotherapy. Pinocembrin, as a specific HDAC7 inhibitor, holds potential as a combination therapy agent to improve immunotherapy response in BCa.

> **中文摘要：**
> 背景：免疫治疗的应答率有限以及个体间结果差异显著，是改善膀胱癌（BCa）患者预后的主要障碍。作为抗肿瘤免疫的核心效应细胞，CD8 + T 细胞在肿瘤中的浸润程度是决定免疫治疗反应的重要因素。组蛋白去乙酰化酶（HDAC）家族成员在调节肿瘤免疫逃逸及免疫治疗敏感性中发挥关键作用，使 HDAC 抑制剂成为临床研究的潜在靶点。
> 
> 方法：研究者利用 IMvigor210 临床试验数据及本中心接受辅助免疫治疗的局部晚期 BCa 患者的随访数据进行回顾性分析，评估 HDAC1–11 表达与免疫治疗反应的关系。通过 RNA 测序、基因集富集分析（GSEA）、染色质免疫共沉淀 PCR（ChIP-PCR）、蛋白共免疫沉淀（Co-IP）、质谱分析、赖氨酸位点突变、RNA 免疫共沉淀及生物信息学分析构建 HDAC7–BTRC–SRSF7–CCL5 信号通路。采用 CD8 + T 细胞共培养实验及人源化 NOG（HuNOG）小鼠肿瘤模型探讨 HDAC7 的免疫调节功能。进一步利用虚拟筛选、微尺度热泳技术（MST）及 HDAC 活性检测筛选潜在 HDAC7 特异性抑制剂，并在携瘤 C57BL/6 小鼠模型中验证松柏素（Pinocembrin）对 BCa 免疫治疗的敏化作用。
> 
> 结果：在 HDAC 家族成员中，仅 HDAC7 表达与免疫治疗反应显著相关。HDAC7 在 BCa 中高表达，并与较差预后相关。功能实验表明，HDAC7 抑制 CD8 + T 细胞浸润，从而降低对 PD-1 抗体治疗的敏感性。在机制上，HDAC7 通过降低剪接调节因子 SRSF7 在赖氨酸 24 位点的乙酰化水平，增强 BTRC 介导的 SRSF7 泛素化降解，从而促进趋化因子 CCL5 mRNA 的加工与表达——而 CCL5 对 CD8 + T 细胞募集至关重要。此外，松柏素被鉴定为一种选择性的 HDAC7 抑制剂，可恢复 CD8 + T 细胞浸润并提升 BCa 免疫治疗疗效。
> 
> 结论：HDAC7 是 BCa 免疫治疗中具有前景的诊断及治疗靶点。作为特异性 HDAC7 抑制剂的松柏素，有望作为联合治疗药物提升 BCa 患者的免疫治疗反应。

### 第二部分 AI 大师评价

本研究系统揭示了 HDAC7 在膀胱癌免疫逃逸中的关键机制，说明其通过调控 SRSF7 乙酰化状态抑制 CCL5 表达并削弱 CD8 + T 细胞浸润。作者利用多组学分析、人源化小鼠模型及功能实验，阐明 HDAC7 对免疫治疗敏感性的负向调节作用，并发现松柏素为其潜在抑制剂，可逆转耐药现象。该工作在阐明 HDAC7 信号通路及开发新型免疫联合疗法方面具有创新性，但仍需更多临床研究验证其安全性与疗效。

---

## 6. 叶酸通过表观遗传修饰改善胎儿生长受限中的胎盘结构与功能。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444682)
**期刊：** Clinical epigenetics
**PMID：** 41444682
**DOI：** 10.1186/s13148-025-01985-y

### 第一部分 原文与翻译

**英文原标题：** Folic acid ameliorates placental structure and function in fetal growth restriction via epigenetic modifications.

> **英文摘要：**
> BACKGROUND: Fetal growth restriction (FGR) is associated with perinatal complications and potential neurodevelopmental risks, yet mechanistic understanding of metabolic dysregulation remains incomplete. We investigated amniotic fluid metabolites as potential functional biomarkers of fetal-placental dysfunction and explored the possibility of folic acid-mediated epigenetic remediation of metabolic imbalances in FGR.
> 
> RESULTS: In FGR amniotic fluid, hypoxanthine was significantly upregulated, valproic acid (VPA) was significantly downregulated, and arginine/proline metabolism pathways were markedly enriched. Folic acid intervention significantly improved fetal growth parameters (crown-rump length, body weight, and placental weight; all P < 0.001). Compensatory labyrinth zone (Lb) hyperplasia was observed in FGR placenta, with a 40% increase in Lb/Jz ratio, while folic acid supplementation reduced Lb proportion by 10% and appeared to restore placental architecture. Epigenetically, folic acid supplementation suppressed histone deacetylases1 (HDAC1) expression, elevated H3K9ac levels and enhanced trophoblast proliferation.
> 
> CONCLUSIONS: Our research suggests that dysregulation of the VPA-hypoxanthine axis may serve as a hallmark of FGR-associated metabolic stress. Folic acid may exerts potential dual therapeutic effects by correcting placental architecture through Lb normalization and initiating epigenetic reprogramming via HDAC1 inhibition and acetylation at lysine 9 of histone H3 (H3K9ac). These findings indicate that folate metabolism could play a regulatory role in placental gene transcription and fetal growth trajectories.

> **中文摘要：**
> 背景：胎儿生长受限（FGR）与围产期并发症及潜在的神经发育风险相关，但其代谢失衡机制的理解仍不完整。我们研究了羊水代谢物作为胎盘-胎儿功能障碍的潜在功能性生物标志物，并探索了叶酸介导的表观遗传途径对FGR代谢失衡的纠正作用。
> 
> 结果：在FGR羊水中，次黄嘌呤显著上调，丙戊酸（VPA）显著下调，精氨酸/脯氨酸代谢通路显著富集。叶酸干预显著改善了胎儿生长参数（头臀长、体重和胎盘重量；均P<0.001）。在FGR胎盘中观察到代偿性迷路层（Lb）增生，Lb/Jz比值增加40%，而叶酸补充使Lb比例降低约10%，并有助于恢复胎盘结构。从表观遗传角度看，叶酸补充抑制了组蛋白去乙酰化酶1（HDAC1）表达，提高了H3K9ac水平，并增强了滋养层细胞增殖。
> 
> 结论：我们的研究表明，VPA–次黄嘌呤轴的失调可能是FGR相关代谢应激的特征性标志。叶酸可能通过Lb结构正常化纠正胎盘结构，并通过HDAC1抑制及组蛋白H3第9位赖氨酸乙酰化（H3K9ac）启动表观遗传重编程，从而发挥双重治疗效应。这些发现提示，叶酸代谢可能在胎盘基因转录调控及胎儿生长轨迹中起关键作用。

### 第二部分 AI 大师评价

本研究聚焦胎儿生长受限的代谢紊乱及表观遗传调控机制，揭示了VPA–次黄嘌呤轴失衡与胎盘功能障碍的关联。通过叶酸干预，研究团队不仅观察到胎盘结构的恢复和胎儿生长指标的改善，还发现HDAC1抑制及H3K9ac水平升高等表观遗传重塑效应。其创新性在于将代谢组学与表观遗传学结合，为FGR的机制研究与干预策略提供了新视角。但研究可能仍需进一步验证叶酸作用的长期发育效应及特异性分子通路。

---

## 7. NHEJ 与核小体复合物的冷冻电镜结构研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444611)
**期刊：** Nature communications
**PMID：** 41444611
**DOI：** 10.1038/s41467-025-67376-2

### 第一部分 原文与翻译

**英文原标题：** Cryo-EM structures of NHEJ assemblies with nucleosomes.

> **英文摘要：**
> DNA double-strand breaks (DSBs) are highly deleterious lesions that can trigger cell death or carcinogenesis if unrepaired or misrepaired. In mammals, most DSBs are repaired by non-homologous end joining (NHEJ), which begins when Ku70/80 binds DNA ends and recruits DNA-PKcs to form the DNA-PK holoenzyme. Although recent cryo-EM studies have resolved several NHEJ assemblies, how these factors access DSBs within nucleosomes remains unclear. Here, we present cryo-EM structures of human Ku70/80 and DNA-PK bound to nucleosomes. Ku70/80 binds the DNA end and bends it away from the nucleosome core, while the Ku70 C-terminal SAP domain makes an additional, specific DNA contact. Our DNA-PK-nucleosome structure further reveals the opening of the Ku80 vWA domain, and we show that non-hydrolysable ATP promotes synapsis by stabilising the Ku80-mediated DNA-PK dimer. These structures reveal a model for DSB recognition on nucleosomal DNA and provide insights relevant to targeting NHEJ in cancer therapy.

> **中文摘要：**
> DNA双链断裂（DSBs）是高度有害的损伤，若未能修复或修复错误，可能引发细胞死亡或致癌。在哺乳动物中，大多数DSBs通过非同源末端连接（NHEJ）途径修复，该途径始于Ku70/80与DNA末端结合并募集DNA-PKcs形成DNA-PK全酶。尽管近年来的冷冻电镜研究已解析出多个NHEJ复合体结构，但这些因子如何在核小体内接近DSBs仍不清楚。本研究报告了人Ku70/80和DNA-PK与核小体结合的冷冻电镜结构。Ku70/80结合在DNA末端并使其远离核小体核心弯曲，同时Ku70的C端SAP结构域与DNA形成额外的特异性接触。我们的DNA-PK–核小体结构进一步揭示了Ku80 vWA结构域的开放，并显示不可水解的ATP通过稳定由Ku80介导的DNA-PK二聚体来促进链对合。这些结构揭示了核小体DNA上DSB识别的模型，并为在癌症治疗中靶向NHEJ提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在解析非同源末端连接（NHEJ）复合物在核小体背景下识别和结合DNA双链断裂的结构机制。作者利用冷冻电镜技术获得了人类Ku70/80及DNA-PK与核小体结合的高分辨率结构，揭示Ku70/80如何弯曲DNA并通过特定结构域进行额外接触，同时发现ATP依赖的DNA-PK二聚体稳定机制。该研究提出了核小体DNA上DSB识别的新模型，为理解NHEJ的空间构型提供重要依据，并对癌症靶向修复途径的药物开发具有潜在启示。其局限在于动态过程尚未完全捕获，仍需结合时间分辨或体内验证研究。

---

## 8. 基于mRNA脂质纳米颗粒的腹腔内定制CAR巨噬细胞程序化以增强癌症免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444487)
**期刊：** Nature communications
**PMID：** 41444487
**DOI：** 10.1038/s41467-025-67674-9

### 第一部分 原文与翻译

**英文原标题：** Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy.

> **英文摘要：**
> Therapeutic strategies for peritoneal metastasis in solid tumors are urgently needed. Programming chimeric antigen receptor macrophages (CAR-Ms) in situ offers opportunities for an unmet demand. However, potential intracellular domains (ICDs) for CAR design and their antitumor mechanisms for macrophage empowerment remain to be explored systematically. By developing a macrophage-targeted mRNA lipid nanoparticle (mRNA-LNP) system, we evaluate 36 CAR formats in CAR-Ms. Tailored CAR-Ms with CD3ζ TLR4 ICDs elicit robust adaptive immune activation and significantly synergize with PD-1/L1 therapy. Single-cell RNA sequencing (scRNA-seq) reveals that CAR-Ms reshape the immunosuppressive tumor microenvironment (TME) and boost the TCF1PD-1 progenitor-exhausted CD8 T cells (Tpex) population. Mechanistically, CAR-Ms maintain a proinflammatory phenotype and simultaneously upregulate MHC-I and PD-L1 by perturbing NF-κB pathways. Collectively, this approach enables intraperitoneal programming of tailored CAR-Ms and broadens understanding of both regulatory and feedback mechanisms for CAR-M therapies against solid tumors.

> **中文摘要：**
> 针对实体瘤腹膜转移的治疗策略亟需发展。原位程序化嵌合抗原受体巨噬细胞（CAR-Ms）为这一未被满足的需求提供了新机遇。然而，用于CAR设计的潜在胞内结构域（ICDs）及其赋能巨噬细胞的抗肿瘤机制仍需系统性探索。通过开发一种靶向巨噬细胞的mRNA脂质纳米颗粒（mRNA-LNP）系统，我们在CAR-Ms中评估了36种CAR构型。携带CD3ζ和TLR4胞内结构域的定制CAR-Ms可诱导强大的适应性免疫激活，并与PD-1/L1治疗表现出显著协同效应。单细胞RNA测序（scRNA-seq）结果显示，CAR-Ms可重塑免疫抑制性的肿瘤微环境（TME），并促进TCF1⁺PD-1⁺前体耗竭性CD8 T细胞（Tpex）群体的扩增。在机制上，CAR-Ms通过扰动NF-κB信号通路维持促炎表型，同时上调MHC-I和PD-L1的表达。总体而言，该方法实现了腹腔内定制CAR-Ms的程序化构建，并拓展了对CAR-M疗法在实体瘤治疗中调控与反馈机制的理解。

### 第二部分 AI 大师评价

本研究旨在通过mRNA脂质纳米颗粒系统实现腹腔内原位编程的定制CAR巨噬细胞，以应对实体瘤腹膜转移治疗的挑战。团队系统评估了多种CAR胞内结构域的构型，发现CD3ζ与TLR4组合能够显著增强免疫活性，并强化与PD-1/L1免疫检查点抑制疗法的联合作用。单细胞测序揭示CAR-Ms可重塑免疫抑制性肿瘤微环境并促进关键效应T细胞群体扩增。该研究创新地拓展了CAR-M在实体瘤免疫治疗中的机制理解，但未来需进一步验证其安全性与体内持久性。

---

## 9. 2022–2024 年利伯维尔“粉红十月”宣传活动期间女性可通过疫苗预防的 HPV 负担及宫颈异常研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444484)
**期刊：** Nature communications
**PMID：** 41444484
**DOI：** 10.1038/s41467-025-67777-3

### 第一部分 原文与翻译

**英文原标题：** Vaccine-preventable HPV burden and cervical abnormalities in women during 2022-2024 Octobre Rose campaigns in Libreville.

> **英文摘要：**
> Cervical cancer is a leading cause of mortality in sub-Saharan Africa, largely driven by persistent carcinogenic human papillomavirus (HPV) infection. We conducted a 3-year cross-sectional study of 1,524 women participating in the national "Octobre Rose" campaigns in Libreville, Gabon. Cervical samples were assessed by visual inspection with acetic acid/Lugol iodine (VIA/VILI) and HPV genotyping using BioPerfectus Multiplex Real-Time PCR assay. Overall HPV prevalence was 21.0%, including 18.5% carcinogenic types and 11.0% covered by the nonavalent vaccine. HPV-35 was dominant, while Gardasil-9-targeted genotypes accounted for 63% of carcinogenic infections and the largest attributable fraction of VIA/VILI-detected abnormalities, particularly HPV-16 and HPV-45. HIV and high lifetime sexual exposure were independent predictors of carcinogenic HPV. These findings reveal a substantial burden of vaccine-preventable HPV in Gabon and underscore the high potential impact of Gardasil-9 implementation, while reinforcing the need for continued HPV-based screening to mitigate residual risk of non-vaccine types such as HPV-35.

> **中文摘要：**
> 宫颈癌是撒哈拉以南非洲地区主要的死亡原因之一，主要由持续性感染致癌型人乳头瘤病毒（HPV）所致。我们开展了一项为期 3 年的横断面研究，纳入了加蓬利伯维尔国家“粉红十月”活动中参与的 1,524 名女性。宫颈样本通过醋酸/Lugol 碘视检法（VIA/VILI）进行评估，并使用 BioPerfectus 多重实时 PCR 检测试剂进行 HPV 基因分型。总体 HPV 感染率为 21.0%，其中 18.5% 为致癌型，11.0% 属于九价疫苗覆盖的类型。HPV-35 是主要感染类型，而 Gardasil-9 所靶向的基因型占致癌感染的 63%，并在 VIA/VILI 检测到的异常中贡献最大，尤其是 HPV-16 和 HPV-45。HIV 感染及终生较高的性暴露是致癌型 HPV 感染的独立预测因素。这些发现揭示了加蓬地区存在显著的可通过疫苗预防的 HPV 负担，强调了九价疫苗实施的潜在巨大影响，同时提示应继续开展基于 HPV 的筛查，以降低非疫苗型（如 HPV-35）带来的残余风险。

### 第二部分 AI 大师评价

本研究通过对加蓬利伯维尔 1,524 名女性的 3 年横断面调查，系统评估了可通过疫苗预防的 HPV 感染和宫颈异常负担。结果指出，HPV-35 是主要流行型别，而 Gardasil-9 所覆盖的型别占致癌感染的大部分，显示出疫苗接种的潜在获益。研究创新地结合了视检与基因分型方法，揭示了疫苗实施与持续筛查在亚撒哈拉非洲地区互为补充的重要性。其局限在于横断面设计限制了因果推断，但为公共卫生决策提供了有价值的地区数据支持。

---

## 10. SERPINB3通过抑制SENP3活性增强NPM1的SUMO化并促进肺肿瘤发生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444337)
**期刊：** Cell death & disease
**PMID：** 41444337
**DOI：** 10.1038/s41419-025-08347-9

### 第一部分 原文与翻译

**英文原标题：** SERPINB3 enhances NPM1 sumoylation via inhibiting SENP3's activity and promotes lung tumorigenesis.

> **英文摘要：**
> SERPINB3 or SCCA1, a member of the serine proteinase inhibitor family, is frequently overexpressed in multiple malignancies, including lung adenocarcinoma (LUAD). However, its molecular mechanisms and endogenous substrates in lung cancer remain poorly characterized. Here, we identified SUMO-specific proteinase 3 (SENP3) as a novel direct interaction partner and functional target of SERPINB3 in LUAD. Using proximity-dependent biotin labeling coupled with mass spectrometry, we discovered that SERPINB3 forms a nuclear complex with SENP3 and nucleophosmin (NPM1). This tripartite interaction was validated through endogenous co-immunoprecipitation and bimolecular fluorescence complementation assays. Structural modeling with AlphaFold3 and subsequent mutagenesis studies revealed that SERPINB3 binds specifically to the N-terminal region of SENP3 (amino acids 265-287). Furthermore, our structural and biochemical analyses demonstrate that SENP3 specifically interacts with the C-terminal aromatic domain of NPM1 (amino acids 242-294), while SERPINB3 selectively binds to the pentameric form of NPM1. Mechanistically, SERPINB3 inhibits SENP3's desumoylation activity, leading to enhanced NPM1 sumoylation in the nucleolus. Functional studies demonstrated that SERPINB3 overexpression (but not the RCL-deleted mutant, SERPINB3△6) promotes LUAD cell proliferation and tumor growth, with NPM1 sumoylation being critical for this oncogenic effect. Clinically, SERPINB3 is highly expressed in human LUAD specimens and co-localizes with SENP3 and NPM1. Our work establishes SENP3 as a bona fide endogenous substrate of SERPINB3 and delineates a novel sumoylation-dependent oncogenic axis in LUAD, offering potential therapeutic targets for this malignancy.

> **中文摘要：**
> SERPINB3，又称SCCA1，是丝氨酸蛋白酶抑制剂家族成员之一，在包括肺腺癌（LUAD）在内的多种恶性肿瘤中常呈过度表达。然而，其在肺癌中的分子机制及内源性底物仍知之甚少。本研究鉴定出SUMO特异性蛋白酶3（SENP3）是SERPINB3在LUAD中新的直接相互作用伙伴和功能靶标。通过依赖邻近标记的生物素标记结合质谱分析，我们发现SERPINB3与SENP3和核仁磷蛋白（NPM1）形成核复合物。这一三元相互作用通过内源性免疫共沉淀及双分子荧光互补实验得到了验证。利用AlphaFold3的结构建模及后续的突变研究表明，SERPINB3特异性结合于SENP3的N端区域（氨基酸265-287）。此外，我们的结构与生化分析显示，SENP3特异性与NPM1的C端芳香结构域（氨基酸242-294）相互作用，而SERPINB3选择性结合NPM1的五聚体形式。从机制上看，SERPINB3抑制SENP3的去SUMO化活性，从而增强核仁中NPM1的SUMO化。功能研究显示，SERPINB3的过表达（而非RCL缺失突变体SERPINB3△6）可促进LUAD细胞增殖与肿瘤生长，且NPM1的SUMO化对这一致癌效应至关重要。在临床上，人类LUAD样本中SERPINB3高表达，并与SENP3及NPM1共定位。本研究确立了SENP3是SERPINB3的真正内源性底物，并阐明了一条依赖SUMO化的LUAD致癌新轴线，为该恶性肿瘤提供了潜在治疗靶点。

### 第二部分 AI 大师评价

该研究通过系统的结构、生化及功能分析揭示了SERPINB3可直接结合并抑制SENP3，从而增强NPM1的SUMO化并促进肺腺癌发生。作者利用邻近标记质谱、AlphaFold3建模及功能验证等综合手段，清晰描绘了SERPINB3–SENP3–NPM1互作网络的分子机制。该工作创新性地确认SENP3为SERPINB3的内源性底物，提出SUMO化依赖的肿瘤促进轴线。其主要局限在于缺乏体内基因修饰模型验证及临床相关性机制解析的深入探讨。

---

## 11. 细胞骨架蛋白KRT14通过调控eIF4H依赖的ACOX2翻译及脂质代谢来主导膀胱癌的顺铂耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444318)
**期刊：** Cell death & disease
**PMID：** 41444318
**DOI：** 10.1038/s41419-025-08369-3

### 第一部分 原文与翻译

**英文原标题：** Cytoskeletal protein KRT14 governs cisplatin resistance by modulating eIF4H-dependent ACOX2 translation and lipid metabolism in bladder cancer.

> **英文摘要：**
> Cisplatin-based chemotherapy remains a mainstay for the treatment of bladder cancer (BLCA); however, its clinical efficacy is frequently compromised by the emergence of chemoresistance, which leads to poor patient outcomes. Although known mechanisms-such as alterations in drug efflux, DNA repair, and key signaling pathways-have been implicated, they fail to fully explain the clinical complexity of cisplatin resistance, indicating that additional molecular drivers remain undiscovered. Keratin 14 (KRT14), an intermediate filament protein associated with aggressive BLCA subtypes, is consistently upregulated in cisplatin-resistant tumors, yet its precise mechanistic role in resistance remains unclear. In this study, we elucidate the functional contribution of KRT14 to cisplatin resistance in BLCA using patient-derived tissues, established cell lines, xenograft mouse models, and a suite of molecular interaction assays. Our results demonstrate that KRT14 is significantly upregulated in BLCA tissues, correlates with poor clinical prognosis, and functionally drives cisplatin resistance both in vitro and in vivo. Mechanistically, we identify a novel and direct interaction between KRT14 and the translation initiation factor eIF4H, specifically through the N-terminal Head domain of KRT14. This interaction modulates the association of eIF4H with the core eIF4F complex, thereby selectively promoting the translation of Acyl-CoA Oxidase 2 (ACOX2) mRNA through its 5' untranslated region. We further show that ACOX2 is essential for mediating the effects of KRT14 on lipid metabolism, cell proliferation, survival, and ultimately, cisplatin resistance. Collectively, our findings reveal that KRT14 contributes to chemoresistance in BLCA not only via its structural roles but also by directly regulating translational machinery through eIF4H, leading to upregulation of the metabolic enzyme ACOX2. The newly defined KRT14-eIF4H-ACOX2 axis orchestrates lipid metabolic reprogramming and cell survival, underscoring the KRT14-eIF4H interface as a promising therapeutic target for overcoming cisplatin resistance in BLCA.

> **中文摘要：**
> 以顺铂为基础的化疗仍然是膀胱癌（BLCA）治疗的主要手段；然而，其临床疗效常因化疗耐药的出现而受损，导致患者预后不良。尽管已有机制——如药物外排、DNA修复及关键信号通路的改变——被认为与耐药相关，但这些机制仍无法充分解释顺铂耐药的临床复杂性，提示尚存在其他未被发现的分子驱动因素。角蛋白14（KRT14）是一种与侵袭性BLCA亚型相关的中间丝蛋白，在顺铂耐药肿瘤中持续上调，但其在耐药过程中的精确机制作用尚不明确。本研究利用患者来源组织、已建立的细胞系、异种移植小鼠模型及多种分子相互作用分析方法，阐明了KRT14在BLCA顺铂耐药中的功能性贡献。结果显示，KRT14在BLCA组织中显著上调，与较差的临床预后相关，并在体内外实验中均能功能性地驱动顺铂耐药。从机制上看，我们鉴定出KRT14与翻译起始因子eIF4H之间一种新颖且直接的相互作用，具体通过KRT14的N端头部结构域介导。该相互作用调控eIF4H与核心eIF4F复合物的结合，从而选择性促进酰基辅酶A氧化酶2（ACOX2）mRNA通过其5'非翻译区的翻译。我们进一步证实，ACOX2对于介导KRT14在脂质代谢、细胞增殖、生存及最终顺铂耐药中的作用是必需的。总体而言，我们的研究结果揭示KRT14在BLCA化疗耐药中不仅通过其结构性作用起效，还可通过eIF4H直接调控翻译装置，从而上调代谢酶ACOX2。新定义的KRT14–eIF4H–ACOX2轴协调脂质代谢重编程和细胞生存，强调了KRT14–eIF4H界面作为克服BLCA顺铂耐药的潜在治疗靶点的价值。

### 第二部分 AI 大师评价

本研究聚焦于膀胱癌中顺铂耐药的分子机制，揭示了KRT14通过与eIF4H相互作用调控ACOX2翻译并影响脂质代谢，从而驱动耐药的关键途径。作者采用患者来源样本、细胞系及动物模型，结合分子互作与翻译调控实验，系统阐明了该机制。发现KRT14–eIF4H–ACOX2信号轴为顺铂耐药提供了新的代谢调控视角，并指向潜在的治疗靶点。该研究创新性强，但仍需进一步验证其在临床转化中的通用性与安全性。

---

## 12. 抑制RNA结合蛋白可增强卵巢癌的免疫治疗效果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444249)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41444249
**DOI：** 10.1038/s41392-025-02515-1

### 第一部分 原文与翻译

**英文原标题：** Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer.

> **英文摘要：**
> High-grade serous ovarian cancer (HGSC) accounts for more than 70% of ovarian cancer-related deaths, yet therapeutic progress remains stagnant. Among the four molecular subtypes reported for HGSC, the C5 subtype is distinguished by high proliferation and immune evasion with an unfavorable MHC-I/PD-L1 ratio. However, the molecular drivers of this immune desert state remain largely undefined. Here, we identify RNA-binding proteins (RBPs) as key regulators of immune evasion in C5-HGSC through integrated single-cell and bulk RNA sequencing. We perform a targeted loss-of-function screen in C5-like cell models and find IGF2BP1 as a central mediator of immune evasion in vitro and in vivo. Mechanistically, IGF2BP1 abrogates interferon-gamma signaling by accelerating IRF1 protein degradation, thereby suppressing MHC-I presentation. We also discover that IGF2BP1 decouples PD-L1 expression from IRF1-dependent transcription and reshapes the immune receptor landscape to limit immune cell infiltration and T cell activation. Therapeutically, the small-molecule BTYNB effectively inhibits IGF2BP1 and synergizes with PD-1 blockade to overcome immune evasion in vivo. Multi-spectral imaging confirms these findings in human HGSC tissues and highlights the role of oncofetal RBPs as molecular drivers of the C5-HGSC subtype. This subtype-wide survey uncovers a previously unrecognized RBP-interferon regulatory axis and establishes RBP inhibition as a therapeutic strategy to enhance immune checkpoint therapy in immunologically cold ovarian tumors.

> **中文摘要：**
> 高级别浆液性卵巢癌（HGSC）占卵巢癌相关死亡的70%以上，但治疗进展仍停滞不前。在已报道的HGSC四种分子亚型中，C5亚型以高增殖和免疫逃逸为特征，并具有不利的MHC-I/PD-L1比例。然而，该免疫“沙漠”状态的分子驱动因素尚未得到明确阐释。本研究通过整合单细胞与总体RNA测序，发现RNA结合蛋白（RBP）是C5-HGSC中免疫逃逸的关键调控因子。我们在C5样细胞模型中进行靶向功能缺失筛选，发现IGF2BP1是体内外免疫逃逸的核心介导分子。从机制上看，IGF2BP1通过加速IRF1蛋白降解来破坏干扰素-γ信号，从而抑制MHC-I呈递。我们还发现，IGF2BP1使PD-L1的表达脱离IRF1依赖的转录调控，并重塑免疫受体景观，以限制免疫细胞浸润和T细胞活化。在治疗层面，小分子BTYNB可有效抑制IGF2BP1，并与PD-1阻断治疗协同作用，体内克服免疫逃逸。多光谱成像在人体HGSC组织中验证了这些发现，并突出了癌胎RBP作为C5-HGSC亚型分子驱动因子的作用。本研究通过亚型范围的系统分析，揭示了先前未识别的RBP–干扰素调控轴，并确立了RBP抑制作为增强免疫检查点治疗的潜在策略，可改善免疫冷型卵巢肿瘤的免疫反应。

### 第二部分 AI 大师评价

本研究聚焦于高级别浆液性卵巢癌C5亚型的免疫逃逸机制，通过整合单细胞及总体转录组分析，确认RNA结合蛋白—特别是IGF2BP1—在调控免疫抑制中的关键作用。作者揭示IGF2BP1通过促进IRF1降解削弱干扰素信号，从而抑制MHC-I呈递并改变PD-L1调控模式。药理学上，RBP抑制剂BTYNB与PD-1阻断剂协同增强抗肿瘤免疫反应。该研究创新性地提出了RBP–干扰素轴的新机制，为改善免疫冷型卵巢癌的免疫治疗提供了理论基础，但仍需进一步临床验证其安全性与疗效。

---

## 13. 吸烟的蛋白质组学特征及其与多样化人群中新发疾病与死亡风险的关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444232)
**期刊：** Nature communications
**PMID：** 41444232
**DOI：** 10.1038/s41467-025-67656-x

### 第一部分 原文与翻译

**英文原标题：** Proteomic signatures of smoking and their associations with risk of incident diseases and mortality in diverse populations.

> **英文摘要：**
> Smoking is the most important behavioural determinant of morbidity and mortality. Using machine learning on plasma levels of 2,917 proteins in the UK Biobank (n = 43,914), we develop a proteomic Smoking Index (pSIN) comprising 51 proteins that accurately distinguish current from never smokers (AUC = 0.95; 95% CI 0.94-0.95). Validation in the China Kadoorie Biobank (n = 3,977) shows similar accuracy (AUC = 0.91; 95% CI 0.89-0.92). pSIN is significantly associated with the risk of all-cause mortality and 18 major chronic diseases, including cardiovascular, renal, pulmonary, neurodegenerative, and cancer outcomes. Among current and former smokers, pSIN predicts death and 11 diseases independently of self-reported smoking history and lifestyle factors. Genome-wide analysis identifies 125 genes (e.g., ALPP, CST5, IL12B) associated with pSIN, while exposome analysis highlights maternal smoking, diet, physical activity, and air pollution as key modifiers. Notably, pSIN tracks recovery among former smokers and identifies those whose disease risks remain comparable to current smokers. These findings demonstrate that plasma proteomics effectively capture the biological imprint of smoking and predict smoking-related morbidity and mortality, offering a more nuanced, molecularly grounded assessment of individual variation in biological response to smoking.

> **中文摘要：**
> 吸烟是影响发病率和死亡率的最重要行为决定因素。通过对英国生物样本库（n = 43,914）中 2,917 种血浆蛋白水平的机器学习分析，我们建立了一个包含 51 种蛋白的蛋白质组学吸烟指数（pSIN），该指数可准确区分当前吸烟者与从未吸烟者（AUC = 0.95；95% CI 0.94–0.95）。在中国 Kadoorie 生物样本库（n = 3,977）中的验证显示了相似的准确性（AUC = 0.91；95% CI 0.89–0.92）。pSIN 与全因死亡风险及 18 种主要慢性疾病（包括心血管、肾脏、肺部、神经退行性及癌症结局）显著相关。在当前和既往吸烟者中，pSIN 能独立于自报吸烟史和生活方式因素预测死亡及 11 种疾病风险。全基因组分析鉴定出 125 个与 pSIN 相关的基因（如 ALPP、CST5、IL12B），而暴露组学分析强调母体吸烟、饮食、体力活动和空气污染为关键调节因素。值得注意的是，pSIN 能够追踪戒烟者的生物学恢复过程，并识别出其疾病风险仍接近当前吸烟者的个体。这些发现表明，血浆蛋白质组可有效捕捉吸烟的生物印记，并预测与吸烟相关的发病率和死亡率，为个体生物学反应差异提供了更细致且基于分子机制的评估。

### 第二部分 AI 大师评价

本研究利用大型生物样本库的蛋白质组数据，运用机器学习方法构建了可量化吸烟影响的蛋白质组学吸烟指数（pSIN）。研究在不同人群中均表现出较高的分类准确性，并揭示了 pSIN 与多种慢性疾病及全因死亡风险的独立关联。通过整合基因组与暴露组数据，文章进一步阐明了吸烟相关分子变化的遗传及环境调控因素。其创新性在于以蛋白质组学方式刻画吸烟的生物学印记，为个体化风险评估提供新的分子工具，但需在更广泛人群与纵向随访中验证其临床应用价值。

---

## 14. GBP2冷凝体通过促进铁死亡增强抗PD-L1免疫治疗对黑色素瘤的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444224)
**期刊：** Nature communications
**PMID：** 41444224
**DOI：** 10.1038/s41467-025-67690-9

### 第一部分 原文与翻译

**英文原标题：** GBP2 condensates promote ferroptosis to sensitize anti-PD-L1 immunotherapy in melanoma.

> **英文摘要：**
> The mechanisms underlying the limited response to immune checkpoint blockade (ICB) remain unclear. One explanation is that tumors escape cytotoxic T cell killing by disrupting interferon-gamma (IFN-γ) signaling. Here we show that guanylate-binding protein 2 (GBP2), an IFN-γ-inducible molecule, functions as a general amplifier of T cell-mediated cytotoxicity by promoting ferroptosis in melanoma. GBP2 enhances STAT1 activation and suppresses SLC7A11, thereby sensitizing tumor cells to ferroptotic death. Upon IFN-γ stimulation, GBP2 undergoes phase separation through an intrinsically disordered region, forming condensates that sequester SHP1 and sustain STAT1 activation. Disrupting GBP2 phase separation impairs ferroptosis, accelerates tumor growth, and weakens T cell-driven tumor control. GBP2 also increases HMGB1 release from ferroptotic cells, promoting cytotoxic T cell infiltration. These findings identify GBP2 as a key mediator linking IFN-γ signaling to ferroptosis and demonstrate that enhancing this pathway can improve tumor responsiveness to ICB immunotherapy.

> **中文摘要：**
> 免疫检查点阻断（ICB）疗法反应受限的机制仍不清楚。一种解释是，肿瘤通过破坏干扰素γ（IFN-γ）信号来逃避免疫细胞毒性T细胞的杀伤作用。本研究表明，鸟苷酸结合蛋白2（GBP2）是一种可被IFN-γ诱导的分子，它通过促进黑色素瘤细胞发生铁死亡，作为T细胞介导细胞毒作用的广泛放大器。GBP2可增强STAT1的激活并抑制SLC7A11的表达，从而使肿瘤细胞对铁死亡更为敏感。在IFN-γ刺激下，GBP2通过其内在无序区发生相分离，形成能够捕获SHP1并维持STAT1活化的凝聚体。破坏GBP2的相分离过程会损害铁死亡、加速肿瘤生长并削弱T细胞介导的肿瘤控制。GBP2还可促进铁死亡细胞释放HMGB1，从而增强细胞毒性T细胞的浸润。这些发现确定了GBP2是连接IFN-γ信号与铁死亡的关键介质，并表明增强该通路可以改善肿瘤对ICB免疫治疗的反应性。

### 第二部分 AI 大师评价

本研究聚焦于IFN-γ信号通路与铁死亡之间的分子联系，揭示GBP2通过相分离形成凝聚体放大STAT1活化，从而增强T细胞介导的细胞毒性并提高抗PD-L1治疗敏感性。作者通过分子、细胞及动物模型多层验证GBP2在肿瘤免疫调控中的作用。研究在机制上创新性地提出GBP2-铁死亡轴的免疫调节功能，为提高ICB疗法疗效提供了新的治疗靶点。然而，该研究的临床转化潜力及在其他肿瘤类型中的普适性仍需进一步验证。

---

## 15. ALDH3A2通过协同诱导铁死亡及铁死亡驱动的巨噬细胞重编程负向调控胃癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41444219)
**期刊：** Cell death & disease
**PMID：** 41444219
**DOI：** 10.1038/s41419-025-08364-8

### 第一部分 原文与翻译

**英文原标题：** ALDH3A2 negatively orchestrates gastric cancer progression through a synergistic induction of ferroptosis and ferroptosis-driven macrophage reprogramming.

> **英文摘要：**
> Gastric cancer (GC) is a prevalent gastrointestinal malignancy in which ferroptosis, mitochondrial dysfunction, and macrophage reprogramming remarkably contribute to disease progression. However, the molecular interplay among these processes in contributing to GC remains poorly understood. In this study, we identified ferroptosis- and mitochondrial dysfunction-related genes (FMDRGs) implicated in GC through bioinformatics analyses. Among them, aldehyde dehydrogenase 3 family member A2 (ALDH3A2) was identified as a key FMDRG significantly downregulated in GC tissues and cell lines. Functional assays revealed that ALDH3A2 overexpression in GC cell lines suppressed proliferation, migration, and invasion while enhancing ferroptosis, effects that were reversed by GPX4 overexpression. ALDH3A2 also impaired the mitochondrial unfolded protein response (UPR) and induced mitochondrial dysfunction. Restoration of UPR ameliorated ALDH3A2-induced mitochondrial dysfunction and ferroptosis. Mechanistically, ALDH3A2 impaired UPR by downregulating SLC47A1 through blockade of NRF2 nuclear translocation, leading to mitochondrial dysfunction, GPX4 downregulation, lipid peroxidation, and subsequent ferroptosis. Synergistically, ALDH3A2-induced ferroptosis promoted IL-6 release, which drove macrophage polarization toward the M1 phenotype with elevated IL-1β production. This macrophage reprogramming, in turn, inhibited GC cell progression by downregulating PD-L1 expression. Therapeutically, both genistein treatment and ALDH3A2 overexpression significantly attenuated GC progression in vitro and in vivo. These findings elucidate ALDH3A2 as a dual regulator of tumor-intrinsic ferroptosis and tumor-extrinsic immune remodeling in contributing to GC pathogenesis, highlighting its potential as a promising therapeutic target in GC.

> **中文摘要：**
> 胃癌（GC）是一种常见的胃肠道恶性肿瘤，其中铁死亡、线粒体功能障碍以及巨噬细胞重编程对疾病进展具有显著贡献。然而，这些过程在GC中相互作用的分子机制仍不清楚。本研究通过生物信息学分析鉴定出参与GC的铁死亡和线粒体功能障碍相关基因（FMDRGs）。其中，发现醛脱氢酶3家族成员A2（ALDH3A2）是一个关键FMDRG，在GC组织和细胞系中显著下调。功能实验表明，在GC细胞系中过表达ALDH3A2可抑制增殖、迁移和侵袭，同时增强铁死亡，这一效应可被GPX4过表达逆转。ALDH3A2还会损害线粒体未折叠蛋白反应（UPR）并诱导线粒体功能障碍。恢复UPR可减轻ALDH3A2诱导的线粒体功能障碍和铁死亡。在机制上，ALDH3A2通过抑制NRF2的核转位下调SLC47A1，从而损害UPR，引发线粒体功能障碍、GPX4下调、脂质过氧化及后续铁死亡。协同地，ALDH3A2诱导的铁死亡促进IL-6释放，驱动巨噬细胞向M1型极化，并增加IL-1β的产生。这种巨噬细胞重编程反过来通过下调PD-L1表达抑制GC细胞的进展。在治疗上，大豆异黄酮（genistein）处理以及ALDH3A2过表达均可在体内外显著减缓GC进展。这些发现揭示ALDH3A2是调控肿瘤内源性铁死亡与肿瘤外源性免疫重塑的双重调节因子，突显其作为GC潜在治疗靶点的价值。

### 第二部分 AI 大师评价

本研究聚焦于ALDH3A2在胃癌中通过铁死亡及免疫重塑调控肿瘤进展的作用。作者结合生物信息学、细胞与动物实验，发现ALDH3A2通过阻断NRF2核转位下调SLC47A1诱导铁死亡，并通过促发IL-6依赖的M1型巨噬细胞极化抑制胃癌生长。研究不仅揭示了ALDH3A2在肿瘤细胞代谢和免疫微环境间的双重作用机制，也提出了ALDH3A2及基于其通路的潜在治疗策略。这为铁死亡相关肿瘤治疗提供了新的分子靶点和理论支持。

---

## 16. 超加工食品摄入的代谢组学特征及其与结直肠癌风险的关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41443985)
**期刊：** Gut
**PMID：** 41443985
**DOI：** 10.1136/gutjnl-2025-335618

### 第一部分 原文与翻译

**英文原标题：** Metabolomic pattern of ultraprocessed food intake and its association with colorectal cancer risk.

> **英文摘要：**
> BACKGROUND: High ultra-processed food (UPF) intake has been linked to colorectal cancer (CRC), but underlying mechanisms remain unclear.
> 
> OBJECTIVE: To evaluate a metabolomic pattern of UPF intake and its association with CRC risk.
> 
> DESIGN: Integrating food frequency questionnaire data and high-throughput metabolomic profiling in 1740 participants (mean age at blood draw: 59.9 years; >95% non-Hispanic white participants) from nested case-control studies within the Nurses' Health Study and Health Professionals Follow-up Study, we derived and validated a UPF-related metabolomic pattern as a weighted sum of metabolites selected via elastic net regression with 10-fold cross-validation. We evaluated prospective associations of this pattern and individual metabolites with CRC risk using multivariable conditional logistic regression in 686 pairs of incident CRC cases and matched controls.
> 
> RESULTS: Among 222 metabolites, we constructed a UPF metabolomic pattern comprising 50 metabolites, primarily lipids and amino acids, with 22 positively and 28 inversely associated with total UPF intake (pattern vs intake: Spearman rho=0.35). The pattern was associated with higher CRC risk (highest vs lowest quintile: OR (95% CI) 1.71 (1.15 to 2.53), p value trend=0.002). Correlations of individual metabolites with UPF intake were moderately aligned with their associations with CRC risk (rho=0.50). N2, N2-dimethylguanosine, a marker of meat/poultry intake, was positively associated with CRC risk (1.96 (1.27 to 3.03)), while 21-deoxycortisol, related to cortisol biosynthesis, was inversely associated (0.59 (0.41 to 0.86)).
> 
> CONCLUSION: We developed a UPF metabolomic pattern. The pattern and several metabolites were associated with CRC risk, providing biological insights into potential pathways underlying the UPF-CRC relationship.

> **中文摘要：**
> 背景：高水平的超加工食品（UPF）摄入与结直肠癌（CRC）风险增加有关，但其潜在机制仍不明确。
> 
> 目的：评估UPF摄入的代谢组学模式及其与CRC风险的关联。
> 
> 研究设计：本研究综合分析了护士健康研究和健康专业人员随访研究中的嵌套病例对照数据，将食物频率问卷数据与高通量代谢组学分析相结合，纳入1740名参与者（采血时的平均年龄为59.9岁；超过95%为非西班牙裔白人）。我们利用弹性网回归与10折交叉验证筛选代谢物，并将其加权求和，推导并验证了与UPF相关的代谢组学模式。随后，采用多变量条件Logistic回归分析686对新发CRC病例与匹配对照，评估该模式及单个代谢物与CRC风险的前瞻性关联。
> 
> 结果：在222种代谢物中，我们构建了一个包含50种代谢物的UPF代谢组学模式，主要包括脂类与氨基酸。其中22种代谢物与UPF总摄入呈正相关，28种呈负相关（模式与摄入的Spearman相关系数ρ=0.35）。该模式与CRC风险升高相关（最高五分位数对比最低五分位数：比值比OR（95%置信区间）1.71（1.15–2.53），趋势检验p=0.002）。单个代谢物与UPF摄入的相关性与其与CRC风险的关联程度中度一致（ρ=0.50）。其中，N2，N2-二甲基鸟苷（肉类/禽肉摄入标志物）与CRC风险呈正相关（OR=1.96（1.27–3.03）），而21-脱氧皮质醇（与皮质醇生物合成相关）则呈负相关（OR=0.59（0.41–0.86））。
> 
> 结论：我们建立了一个与UPF摄入相关的代谢组学模式。该模式及若干代谢物与CRC风险显著相关，为揭示UPF与CRC之间潜在生物学途径提供了新的见解。

### 第二部分 AI 大师评价

该研究通过将大规模代谢组学数据与饮食调查数据整合，创新性地构建了超加工食品摄入的代谢特征模式，并验证其与结直肠癌风险的相关性。结果表明，UPF相关代谢特征显著预测较高的CRC风险，部分代谢物可能揭示脂质代谢与激素通路在其中的作用。研究为理解饮食加工度与癌症风险的生物机制提供了实证支持，具有较强的临床与公共卫生意义。其局限性包括人群种族单一及因果推断受限。

---

## 17. 结肠憩室病全球指南修订版：菲耶索莱共识报告

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41443984)
**期刊：** Gut
**PMID：** 41443984
**DOI：** 10.1136/gutjnl-2025-336902

### 第一部分 原文与翻译

**英文原标题：** Revised version global guidelines on diverticular disease of the colon: the Fiesole Consensus report.

> **英文摘要：**
> INTRODUCTION: Colonic diverticulosis is the most common structural abnormality of the colon in developed countries, with an increasing global prevalence. Approximately 20-25% of affected individuals develop symptoms, collectively referred to as diverticular disease. Given its wide clinical spectrum, evolving pathophysiological insights and growing disease burden, updated guidance is essential.
> 
> METHODS: This International Consensus, developed by 32 experts from 14 countries through a structured Delphi process based on the PICO framework and GRADE methodology, provides evidence-based recommendations across five domains: epidemiology and pathogenesis; clinical features; diagnosis; medical therapy; and surgical management.
> 
> RESULTS: Key statements define diverticulosis as the presence of diverticula without symptoms and diverticular disease as diverticula associated with symptoms or complications. High dietary fibre intake is protective whereas smoking, obesity and the use of non-steroidal anti-inflammatory drugs, corticosteroids, opioids or immunotherapy increase risk. Imaging is essential in suspected acute diverticulitis: ultrasound may be appropriate in experienced hands, while CT remains preferred for complicated cases. Diverticulosis itself requires no treatment. In symptomatic uncomplicated diverticular disease, dietary fibre, selected probiotics, mesalazine and rifaximin may help relieve symptoms. Routine antibiotic use is not recommended for acute uncomplicated diverticulitis, and elective surgery should be individualised, prioritising quality of life considerations over episode count.
> 
> CONCLUSIONS: These Consensus statements aim to standardise and optimise the diagnosis, management and prevention of diverticular disease across diverse healthcare systems, while highlighting research priorities such as microbiome characterisation, genetic risk profiling and long-term outcomes of selective antimicrobial and surgical strategies.

> **中文摘要：**
> 引言：结肠憩室病是发达国家中最常见的结肠结构异常，且其全球患病率正不断上升。大约20-25%的患者会出现症状，统称为憩室病。鉴于其广泛的临床谱系、不断发展的病理生理学认识以及日益增长的疾病负担，更新指南势在必行。
> 
> 方法：本国际共识由来自14个国家的32位专家通过基于PICO框架和GRADE方法的结构化德尔菲过程制定，围绕五个核心领域提出循证推荐：流行病学与发病机制、临床特征、诊断、内科治疗及外科管理。
> 
> 结果：主要声明指出，憩室病可定义为存在无症状的憩室，而憩室疾病则指伴有症状或并发症的憩室。高膳食纤维摄入具有保护作用，而吸烟、肥胖以及使用非甾体抗炎药、糖皮质激素、阿片类药物或免疫治疗会增加风险。在怀疑急性憩室炎的情况下，影像学检查至关重要：在有经验者操作下，超声检查可能合适，但CT仍是复杂病例的首选。单纯憩室病本身无需治疗。在有症状的非复杂性憩室疾病中，高纤维饮食、特定益生菌、美沙拉嗪及利福昔明可能有助于缓解症状。不推荐常规使用抗生素治疗急性非复杂性憩室炎；择期手术应个体化，重视生活质量而非发作次数。
> 
> 结论：这些共识声明旨在跨越多样化的医疗体系，规范和优化憩室疾病的诊断、管理与预防，同时强调未来的研究重点，包括微生物组特征分析、遗传风险谱研究及选择性抗菌与外科策略的长期结局。

### 第二部分 AI 大师评价

该研究基于多国专家德尔菲法共识，系统修订了全球结肠憩室疾病的诊疗指南。文章涵盖从流行病学到外科管理的全流程循证推荐，强调了高纤维饮食的保护作用及避免不必要的抗生素使用。其创新之处在于提出了生活质量导向的手术决策框架，并关注微生物组与遗传因素在疾病中的作用。该报告有助于国际标准化诊疗流程，但仍需未来研究验证长期实施效果。

---

## 18. 种系与体细胞功能缺失突变的比较揭示了不同的基因型–表型关联，并为结直肠肿瘤发生的遗传机制提供了新的见解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41443981)
**期刊：** Gut
**PMID：** 41443981
**DOI：** 10.1136/gutjnl-2025-337030

### 第一部分 原文与翻译

**英文原标题：** Comparison between germline and somatic loss-of-function  mutations reveals different genotype-phenotype associations and provides insights into the genetic mechanisms of colorectal tumourigenesis.

> **英文摘要：**
> BACKGROUND: Germline  mutations cause a dominantly inherited syndrome of colorectal cancer (CRC) and serrated polyps. However, these data originate from highly selected families.
> 
> OBJECTIVE: We assessed germline  variants in patients more representative of the general population and compared these with somatic mutations in CRCs.
> 
> DESIGN: We studied 49 823 CRC and/or polyp cases from the CORGI study, 100 000 Genomes (100kGP) and UK Biobank (UKB), alongside 165 250 controls. Somatic mutations were analysed in 2722 CRCs.
> 
> RESULTS: Consistent with the literature, a germline loss-of-function  variant (p.Thr158ProfsTer6) was found in a multigenerational CORGI family with early-onset CRC and serrated and/or filiform polyps. However, while 23 CRC/polyp cases and 47 controls from 100kGP or UKB had germline  mutations, cases often lacked multiple polyps or a notable family history. Sometimes, CRCs developed independently of the germline  mutation. In case-control analyses, germline  variants were associated with CRC risk (OR=2.696, p=0.010), but penetrance was much greater for germline mutations in the N-terminal half of the gene. Germline C-terminal mutations conferred no increased CRC risk. However, somatic C-terminal mutations were pathogenic, perhaps because their relatively weak effects are supplemented by accompanying mutations in Wnt genes, including  and a new driver, .
> 
> CONCLUSION: is a CRC predisposition gene, but risks are moderate, the reported polyposis phenotype is often absent and molecular phenocopies can occur. N-terminal germline  variants confer higher risk, although weak effects of C-terminal variants cannot be excluded. Genetic testing and patient management should incorporate these factors.

> **中文摘要：**
> 背景：种系突变可导致结直肠癌（CRC）及锯齿状息肉的显性遗传综合征。然而，这些数据主要来自高度选择的家系。
> 
> 目的：我们评估了更具代表性人群中的种系变异，并将其与CRC中的体细胞突变进行比较。
> 
> 设计：本研究分析了来自CORGI研究、10万基因组计划（100kGP）和英国生物样本库（UKB）的49,823例CRC和/或息肉病例，以及165,250例对照。另对2,722例CRC样本进行了体细胞突变分析。
> 
> 结果：与文献报道一致，在一个具有早发CRC及锯齿状和/或线形息肉的多代CORGI家系中发现了一个种系功能缺失变异（p.Thr158ProfsTer6）。然而，在100kGP或UKB中，23例CRC/息肉病例和47例对照存在种系突变，但患者往往缺乏多发性息肉或明显的家族史。有时，CRC可独立于该种系突变发生。病例–对照分析显示，种系变异与CRC风险相关（OR=2.696，p=0.010），但位于基因N端部分的种系突变具有更高的外显率。C端种系突变未增加CRC风险。相比之下，C端体细胞突变具有致病性，可能是由于其较弱效应被伴随的Wnt通路基因突变（包括已知基因及一个新的驱动基因）所增强。
> 
> 结论：该基因是CRC的易感基因，但风险属中等，报告的多发息肉表型常缺失，且可能出现分子表型拟像。N端种系变异赋予较高风险，尽管不能排除C端变异的轻度效应。基因检测与患者管理应充分考虑这些因素。

### 第二部分 AI 大师评价

本文通过系统比较种系与体细胞功能缺失突变在结直肠癌中的差异，揭示了不同突变区段的基因型–表型关联。研究样本量庞大，结合多项队列和基因组数据，增强了结果的普适性。其发现N端种系突变具有更高外显率，而C端突变风险较低，但在体细胞环境中可致病，为理解结直肠癌遗传机制提供了新见解。创新性在于揭示了“同基因不同突变类型”的风险差异，但仍受限于数据中函数机制验证不足。

---

## 19. Rb1缺失在乳腺癌细胞系和患者来源的异种移植模型中通过ATR与PKMYT1双重抑制诱导合成致死效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41442499)
**期刊：** Science translational medicine
**PMID：** 41442499
**DOI：** 10.1126/scitranslmed.adx6797

### 第一部分 原文与翻译

**英文原标题：** Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts.

> **英文摘要：**
> Targeting cell cycle checkpoints has emerged as a promising strategy in cancer therapy, yet single-agent inhibitors often fail because of compensatory mechanisms. Here, we demonstrate that coinhibition of ATR (RP-3500) and PKMYT1 (RP-6306) induces synthetic lethality in Rb1-deficient breast cancers by disrupting both S-G and G-M checkpoints. This leads to replication stress, premature mitotic entry, and accumulation of DNA damage. In vitro, Rb1-deficient breast cancer cells exhibited marked apoptosis and loss of clonogenic survival, whereas Rb1-proficient models remained resistant to combination treatment. Genetic manipulation confirmed this dependency: Rb1 knockdown sensitized resistant models, whereas reexpression conferred protection. In vivo, patient-derived xenograft (PDX) models recapitulated these findings. Rb1-deficient tumors regressed after ATR/PKMYT1 coinhibition, whereas Rb1-proficient tumors showed only modest responses. Combination therapy was well tolerated without weight loss or measurable toxicity. Biomarker analysis revealed increased γH2AX and reduced Ki67 staining exclusively in Rb1-deficient PDX models, underscoring the specificity of this response. Mechanistically, Rb1 loss impaired double-strand DNA repair by attenuating homologous recombination and nonhomologous end joining, leading to replication fork collapse, chromosomal instability, and mitotic catastrophe. Proteogenomic analysis identified JNK/p38 stress response pathway activation as a key driver of apoptosis after ATR/PKMYT1 inhibition in Rb1-deficient cells. Clinically, a retrospective analysis of stage IV breast cancer datasets revealed that Rb1-low tumors display reduced DNA repair pathway activity in triple-negative and CDK4/6 inhibitor-resistant luminal breast cancers. These results identify Rb1 loss as a predictive biomarker for ATR/PKMYT1-targeted therapy, offering a potential precision treatment strategy for advanced breast cancers.

> **中文摘要：**
> 以细胞周期检查点为靶点的治疗已成为癌症治疗中一种极具前景的策略，但单药抑制剂往往因代偿机制而疗效有限。本研究表明，ATR（RP-3500）与PKMYT1（RP-6306）的双重抑制可通过破坏S-G和G-M检查点，在Rb1缺失的乳腺癌中诱导合成致死作用。这一过程导致复制应激、过早的有丝分裂进入以及DNA损伤的积累。在体外实验中，Rb1缺失的乳腺癌细胞表现出显著的凋亡和克隆形成能力丧失，而Rb1功能完整的模型对联合治疗仍具抗性。遗传学操作证实了这种依赖性：Rb1敲低可使耐药模型敏感，而Rb1再表达则可恢复保护作用。在体内实验中，患者来源的异种移植（PDX）模型重现了这些发现。Rb1缺失的肿瘤在ATR/PKMYT1双重抑制后出现显著缩小，而Rb1功能完整的肿瘤仅表现出轻微反应。联合治疗耐受性良好，无体重下降或明显毒性。生物标志物分析显示，Rb1缺失的PDX模型中γH2AX表达升高、Ki67染色降低，突显反应的特异性。在机制上，Rb1的缺失通过削弱同源重组和非同源末端连接途径，损害双链DNA修复，导致复制叉塌陷、染色体不稳定和有丝分裂灾难。蛋白组学与基因组联合分析鉴定出JNK/p38应激反应通路的激活是ATR/PKMYT1抑制后诱导Rb1缺失细胞凋亡的关键驱动因素。在临床上，对IV期乳腺癌数据集的回顾性分析发现，Rb1低表达的肿瘤在三阴性及CDK4/6抑制剂耐药的Luminal型乳腺癌中表现出DNA修复通路活性降低。这些结果表明，Rb1缺失可作为ATR/PKMYT1靶向治疗的预测性生物标志物，为晚期乳腺癌提供了一种潜在的精准治疗策略。

### 第二部分 AI 大师评价

本文通过多层次体内外模型证明了ATR与PKMYT1双重抑制在Rb1缺失乳腺癌中的合成致死效应，揭示了细胞周期检查点与DNA修复通路间的关键联系。研究不仅阐明了Rb1缺失导致的复制应激和DNA修复障碍机制，还识别了JNK/p38通路在诱导凋亡中的核心作用。临床关联分析进一步强化了Rb1作为ATR/PKMYT1靶向治疗预测性生物标志物的潜力。该研究为乳腺癌精准治疗提供了新思路，但后续仍需在临床试验中验证疗效与安全性。

---

## 20. 全基因组筛选发现 Runx2 是造血干细胞扩增和 T 细胞分化的新型调控因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40961240)
**期刊：** Blood
**PMID：** 40961240
**DOI：** 10.1182/blood.2025029115

### 第一部分 原文与翻译

**英文原标题：** A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment.

> **英文摘要：**
> Self-renewing multipotent hematopoietic stem cells (HSCs) are a rare but important cell population that can reconstitute the entire blood and immune system after transplantation. Due to their rarity, it has been difficult to comprehensively study the mechanisms regulating HSC activity. However, recent improvements in hematopoietic stem and progenitor cell (HSPC) culture methods using polyvinyl alcohol-based media now facilitate large-scale ex vivo HSC expansion. Here, we performed a genome-wide CRISPR knockout (KO) screen in primary mouse HSPCs to discover novel regulators of ex vivo expansion. The screen identified Runx2 as a strong negative regulator of HSC expansion, which we validated using ex vivo and in vivo assays. Loss of Runx2 increased the frequency of immunophenotypic HSCs in HSPC cultures by approximately threefold. After expansion, these Runx2-KO HSCs engrafted at approximately fivefold higher levels in transplantation assays. Noncultured Runx2-KO HSCs also displayed enhanced reconstitution potential, but loss of Runx2 did not alter blood parameters. Notably, however, T-cell reconstitution was diminished from Runx2-KO HSCs, and we further validated an additional role for Runx2 in T-cell commitment using ex vivo and in vivo assays. In summary, we have identified a multifaceted role for Runx2 in HSCs, as a negative regulator of HSC self-renewal and as a facilitator of T-cell commitment. These results contribute to our understanding of the transcriptional regulation of hematopoiesis and HSC therapies.

> **中文摘要：**
> 具有自我更新能力的多能造血干细胞（HSC）是一类稀有但重要的细胞群体，在移植后能够重建整个血液和免疫系统。由于其稀有性，全面研究调控 HSC 活性的机制一直较为困难。然而，近期基于聚乙烯醇培养基的造血干/祖细胞（HSPC）培养方法的改进，使得体外大规模扩增 HSC 成为可能。在本研究中，我们在小鼠原代 HSPC 中开展了全基因组 CRISPR 敲除筛选，以发现调控体外扩增的新因子。筛选结果鉴定出 Runx2 是 HSC 扩增的强负调控因子，并通过体外和体内实验加以验证。Runx2 缺失使 HSPC 培养中免疫表型 HSC 的比例约增加三倍。扩增后，这些 Runx2 敲除的 HSC 在移植实验中的嵌合水平提高约五倍。未经培养的 Runx2 敲除 HSC 同样表现出增强的重建潜能，但 Runx2 的缺失并未改变血液学参数。值得注意的是，Runx2 缺失 HSC 的 T 细胞重建能力下降，我们进一步通过体内外实验验证了 Runx2 在 T 细胞分化中的额外作用。总之，我们揭示了 Runx2 在 HSC 中的多重作用：既是抑制 HSC 自我更新的负调控因子，又是促进 T 细胞分化的关键调节者。这些结果加深了我们对造血过程及 HSC 转录调控机制的理解，并为 HSC 治疗提供了新的思路。

### 第二部分 AI 大师评价

本研究通过大规模 CRISPR 敲除筛选，系统鉴定出转录因子 Runx2 是造血干细胞体外扩增的关键负调控因子。研究结合体外扩增和体内移植实验揭示 Runx2 缺失能显著增强 HSC 的自我更新与重建能力，同时在 T 细胞分化中发挥促进作用。这一发现为理解造血干细胞命运调控提供了新的分子靶点，具有潜在的临床价值。其创新性在于全基因组层面揭示了 Runx2 的双重功能，但后续仍需探讨其在不同造血谱系中的精确调控机制。

---

速递结束，祝您工作愉快！